Changlin Tian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Changlin Tian has a total of 590 co-authors. Here are the top co-authors by number of shared publications:
- Lei Liu
New Cornerstone Science Laboratory, Tsinghua-Peking Joint Center for Life Sciences, Ministry of Education Key Laboratory of Bioorganic Phosphorus Chemistry and Chemical Biology, Center for Synthetic and Systems Biology, Department of Chemistry, Tsinghua University, Beijing, China
24 shared publications Longhua Zhang
Hefei National Research Center for Physical Sciences at the Microscale, Division of Life Sciences and Medicine, Anhui Engineering Laboratory of Peptide Drug, University of Science and Technology of China, Hefei, Anhui, China
22 shared publications- Lu Yu
University of Science and Technology of China
19 shared publications Demeng Sun
Division of Life Sciences and Medicine, Joint Center for Biological Analytical Chemistry, Anhui Engineering Laboratory of Peptide Drug, University of Science and Technology of China, Hefei, China
17 shared publicationsPan Shi
School of Life Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230026, P. R. China
17 shared publications- Pan Shi
Department of Endocrinology, the First Affiliated Hospital of USTC, School of Life Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Anhui, P. R. China
17 shared publications
Latest Publications
- 10 November 2026
- Published by American Chemical Society (ACS) in Analytical Chemistry
Engineered MSC-Derived Nanovesicles Delivering Cascade-Responsive Self-Assembling Gd-Based Contrast Agents for Enhanced T2-Weighted MRI of Glioblastoma
The clinical management of glioblastoma (GBM) remains severely constrained by the blood−brain barrier (BBB), which impedes both diagnostic and therapeutic interventions. Here, we present an innovative bioengineered platform (hMSC-NV-Gd-CBT) based on human mesenchymal stem cell-derived nanovesicles (hMSC-NVs) that are covalently modified with a self-assembling, small-molecule Gd-based contrast agent (N3-Gd-CBT). These nanovesicles retain the inherent BBB-penetrating capacity of their parent cells while offering substantially higher production yields than conventional hMSC-derived exosomes. Furthermore, the incorporation of glutathione/cathepsin B (CTSB) cascade-responsive self-assembling probe N3-Gd-CBT enables tumor-specific aggregation and accumulation of contrast agents, significantly enhancing T2-weighted MRI contrast in GBM. Systematic evaluation at 9.4 T reveals that hMSC-NV-Gd-CBT generates superior MRI contrast for GBM compared with the free N3-Gd-CBT probe, hMSC-NV-Gd-CBT co-treated with a CTSB inhibitor, and commercial Gd-DTPA. This strategy not only provides a novel diagnostic tool for brain tumors and other neurodegenerative diseases but also opens new avenues for developing next-generation T2-weighted MRI contrast agents.
- 10 November 2026
- Published by American Chemical Society (ACS) in Analytical Chemistry
Engineered MSC-Derived Nanovesicles Delivering Cascade-Responsive Self-Assembling Gd-Based Contrast Agents for Enhanced T2-Weighted MRI of Glioblastoma
The clinical management of glioblastoma (GBM) remains severely constrained by the blood−brain barrier (BBB), which impedes both diagnostic and therapeutic interventions. Here, we present an innovative bioengineered platform (hMSC-NV-Gd-CBT) based on human mesenchymal stem cell-derived nanovesicles (hMSC-NVs) that are covalently modified with a self-assembling, small-molecule Gd-based contrast agent (N3-Gd-CBT). These nanovesicles retain the inherent BBB-penetrating capacity of their parent cells while offering substantially higher production yields than conventional hMSC-derived exosomes. Furthermore, the incorporation of glutathione/cathepsin B (CTSB) cascade-responsive self-assembling probe N3-Gd-CBT enables tumor-specific aggregation and accumulation of contrast agents, significantly enhancing T2-weighted MRI contrast in GBM. Systematic evaluation at 9.4 T reveals that hMSC-NV-Gd-CBT generates superior MRI contrast for GBM compared with the free N3-Gd-CBT probe, hMSC-NV-Gd-CBT co-treated with a CTSB inhibitor, and commercial Gd-DTPA. This strategy not only provides a novel diagnostic tool for brain tumors and other neurodegenerative diseases but also opens new avenues for developing next-generation T2-weighted MRI contrast agents.
- Open Access
- 4 November 2026
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 17 (42) , 20422-20430
Sortase-mediated generation of various macrocyclic peptide scaffolds from low-reactivity electrophilic substrates
We report the compatibility of sortase with various low-reactivity electrophilic peptide substrates, which will provide a useful chemoenzymatic method for constructing cyclic peptide libraries with diverse frameworks.
- 4 November 2026
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 17 (42) , 20422-20430
Open AccessSortase-mediated generation of various macrocyclic peptide scaffolds from low-reactivity electrophilic substrates
We report the compatibility of sortase with various low-reactivity electrophilic peptide substrates, which will provide a useful chemoenzymatic method for constructing cyclic peptide libraries with diverse frameworks.
- Open Access
- 31 October 2026
- Published by Springer Nature in Nature Communications
Chemoreceptor TRPγ coordinates locomotor activity via regulating intracellular Ca2+ homeostasis in Drosophila
- 31 October 2026
- Published by Springer Nature in Nature Communications
Open AccessChemoreceptor TRPγ coordinates locomotor activity via regulating intracellular Ca2+ homeostasis in Drosophila
- 1 October 2026
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 148 (40) , 43356-43365
Monofluoromethylphenylalanine: A Sensitive 19F Probe for Protein Conformational Dynamics In Vitro and in Cells
The combination of site-specific incorporation of 19F-labeled unnatural amino acids (UAAs) and 19F nuclear magnetic resonance (NMR) spectroscopy is a powerful strategy for investigating protein structure, dynamics, and interactions. However, commonly used 19F-containing UAAs often suffer from narrow chemical shift dispersion and low sensitivity to environmental or protein conformational changes, especially in complex cellular conditions. Herein, we report a 19F-labeled unnatural amino acid, monofluoromethylphenylalanine (mfmF, CH2F-Phe), which displays superior spectroscopic properties for both in vitro and in-cell 19F NMR studies. Using genetic code expansion, CH2F-Phe was efficiently site-specifically incorporated into two model proteins light-oxygen-voltage sensing domain 2 (LOV2) and Calmodulin (CaM). Compared to trifluoromethylphenylalanine (CF3-Phe), CH2F-Phe exhibits broader 19F chemical shift dispersion and markedly enhanced sensitivity to environmental changes. Using this synthesized 19F NMR probe, we successfully achieved sensitive detection of the light-induced conformational transition of LOV2 in vitro. Furthermore, CH2F-Phe-incorporated CaM displayed remarkably sensitive and substantially larger 19F chemical shift differences (>1.0–2.0 ppm) between the apo- and Ca2+-bound states compared to CF3-Phe-labeled CaM, enabling the detection of previously unresolved intermediate states during Ca2+-dependent conformational transitions in living cells. Collectively, CH2F-Phe serves as an invaluable probe to characterize protein dynamics and interactions.
- 1 October 2026
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 148 (40) , 43356-43365
Monofluoromethylphenylalanine: A Sensitive 19F Probe for Protein Conformational Dynamics In Vitro and in Cells
The combination of site-specific incorporation of 19F-labeled unnatural amino acids (UAAs) and 19F nuclear magnetic resonance (NMR) spectroscopy is a powerful strategy for investigating protein structure, dynamics, and interactions. However, commonly used 19F-containing UAAs often suffer from narrow chemical shift dispersion and low sensitivity to environmental or protein conformational changes, especially in complex cellular conditions. Herein, we report a 19F-labeled unnatural amino acid, monofluoromethylphenylalanine (mfmF, CH2F-Phe), which displays superior spectroscopic properties for both in vitro and in-cell 19F NMR studies. Using genetic code expansion, CH2F-Phe was efficiently site-specifically incorporated into two model proteins light-oxygen-voltage sensing domain 2 (LOV2) and Calmodulin (CaM). Compared to trifluoromethylphenylalanine (CF3-Phe), CH2F-Phe exhibits broader 19F chemical shift dispersion and markedly enhanced sensitivity to environmental changes. Using this synthesized 19F NMR probe, we successfully achieved sensitive detection of the light-induced conformational transition of LOV2 in vitro. Furthermore, CH2F-Phe-incorporated CaM displayed remarkably sensitive and substantially larger 19F chemical shift differences (>1.0–2.0 ppm) between the apo- and Ca2+-bound states compared to CF3-Phe-labeled CaM, enabling the detection of previously unresolved intermediate states during Ca2+-dependent conformational transitions in living cells. Collectively, CH2F-Phe serves as an invaluable probe to characterize protein dynamics and interactions.
- 1 September 2026
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 62 (68) , 17041-17045
Screening, synthesis and structural characterization of a novel bicyclic peptide inhibiting α7 nicotinic acetylcholine receptor
De novo discovery of an unnatural and potent bicyclic peptide through a phage-encoded library.
- 1 September 2026
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 62 (68) , 17041-17045
Screening, synthesis and structural characterization of a novel bicyclic peptide inhibiting α7 nicotinic acetylcholine receptor
De novo discovery of an unnatural and potent bicyclic peptide through a phage-encoded library.
- Open Access
- 20 July 2026
- Published by Springer Nature in Communications Biology
- Vol. 9 (1)
The Kv1.3 blocker PAP‑1 alleviates psoriasis‑like dermatitis in rats via suppressing inflammation and angiogenesis
Psoriasis is a chronic inflammatory skin disorder driven by epidermal hyperplasia, immune infiltration, and pathological angiogenesis. PAP‑1, a selective Kv1.3 channel blocker, exhibits therapeutic potential, though its underlying mechanisms remain incompletely understood. Here, we show that both preventive and therapeutic administration of PAP‑1 markedly attenuates imiquimod (IMQ)-induced psoriasis‑like skin lesions and reduces splenomegaly in male rats. RNA sequencing revealed that PAP-1 downregulated genes associated with inflammation and angiogenesis, accompanied by decreased levels of pro-inflammatory cytokines and vascular markers. PAP-1 also inhibited VEGF-A-induced HUVEC proliferation, migration, invasion, and tube formation. Mechanistically, PAP-1 not only blocked Kv1.3 currents, but also suppressed Kv1.3 expression in the skin of IMQ-induced psoriasis-like male rats and VEGF-A-induced HUVECs. Cryo-EM structural analysis revealed that PAP-1 binds within the central cavity of Kv1.3, beneath the selectivity filter, in an inactivated state. These results establish that preventive and therapeutic PAP-1 alleviates psoriasis-like dermatitis via dual anti-inflammatory and anti-angiogenic mechanisms, supporting its further therapeutic development.
- 20 July 2026
- Published by Springer Nature in Communications Biology
- Vol. 9 (1)
Open AccessThe Kv1.3 blocker PAP‑1 alleviates psoriasis‑like dermatitis in rats via suppressing inflammation and angiogenesis
Psoriasis is a chronic inflammatory skin disorder driven by epidermal hyperplasia, immune infiltration, and pathological angiogenesis. PAP‑1, a selective Kv1.3 channel blocker, exhibits therapeutic potential, though its underlying mechanisms remain incompletely understood. Here, we show that both preventive and therapeutic administration of PAP‑1 markedly attenuates imiquimod (IMQ)-induced psoriasis‑like skin lesions and reduces splenomegaly in male rats. RNA sequencing revealed that PAP-1 downregulated genes associated with inflammation and angiogenesis, accompanied by decreased levels of pro-inflammatory cytokines and vascular markers. PAP-1 also inhibited VEGF-A-induced HUVEC proliferation, migration, invasion, and tube formation. Mechanistically, PAP-1 not only blocked Kv1.3 currents, but also suppressed Kv1.3 expression in the skin of IMQ-induced psoriasis-like male rats and VEGF-A-induced HUVECs. Cryo-EM structural analysis revealed that PAP-1 binds within the central cavity of Kv1.3, beneath the selectivity filter, in an inactivated state. These results establish that preventive and therapeutic PAP-1 alleviates psoriasis-like dermatitis via dual anti-inflammatory and anti-angiogenic mechanisms, supporting its further therapeutic development.
- Open Access
- 6 May 2026
- Published by Springer Nature in European Radiology Experimental
- Vol. 10 (1)
9.4-T MRI monitoring of early MASH progression and therapeutic response in a prefibrotic mouse model
Objective: Early intervention in metabolic dysfunction-associated steatohepatitis (MASH) is critical to halt disease progression. However, noninvasive tools for monitoring early-stage MASH and therapeutic efficacy in preclinical models remain limited, impeding preclinical drug development. This study establishes an integrated approach using multiparametric magnetic resonance imaging (MRI) at 9.4 T to dynamically track disease development and drug response in a prefibrotic MASH mouse model. Materials and methods: Mice were fed a high-fat and high-cholesterol diet (HFHCD) for 16 weeks to induce early MASH without fibrosis and treated with the anti-MASH drug semaglutide for 8 weeks after modeling. Longitudinal MRI assessments—including proton density fat fraction (PDFF), 1 H magnetic resonance spectroscopy (MRS), T 2 mapping, and diffusion-weighted imaging (DWI)—were performed every 4 weeks and correlated with histopathology. Results: Histology confirmed early MASH after 16 weeks, without fibrosis. All MRI parameters strongly correlated with histopathological scores. HFHCD feeding led to significant changes: PDFF, MRS-derived liver fat content (LFC), and T 2 values increased by 6.8-, 5.2-, and 2.5-fold, respectively, while apparent diffusion coefficient (ADC) decreased by 30% ( p < 0.001). T 2 and ADC also correlated with MRS-quantified saturated fatty acids. Semaglutide treatment effectively reversed these changes: PDFF decreased by 73%, LFC by 62%, T 2 by 46% ( p < 0.001), and ADC increased 1.4-fold ( p = 0.017) compared to the vehicle group. Conclusion: This work demonstrates multiparametric MRI as a powerful noninvasive platform for monitoring early MASH dynamics and treatment response. By enabling longitudinal assessment in a prefibrotic model, this approach accelerates translational research in MASH diagnosis and drug development. Relevance statement: The established multiparametric MRI evaluation system provides a valuable noninvasive monitoring platform for preclinical early-stage MASH research, demonstrating significant potential to accelerate the translational progress in MASH diagnosis and drug development. Key Points: A novel prefibrotic MASH model was established to assess early-stage MASH progression. Multiparametric MRI at 9.4 T enables noninvasive, longitudinal monitoring of early MASH. Semaglutide-induced improvement in steatosis and inflammation can be monitored by multiparametric MRI. Graphical
- 6 May 2026
- Published by Springer Nature in European Radiology Experimental
- Vol. 10 (1)
Open Access9.4-T MRI monitoring of early MASH progression and therapeutic response in a prefibrotic mouse model
Objective: Early intervention in metabolic dysfunction-associated steatohepatitis (MASH) is critical to halt disease progression. However, noninvasive tools for monitoring early-stage MASH and therapeutic efficacy in preclinical models remain limited, impeding preclinical drug development. This study establishes an integrated approach using multiparametric magnetic resonance imaging (MRI) at 9.4 T to dynamically track disease development and drug response in a prefibrotic MASH mouse model. Materials and methods: Mice were fed a high-fat and high-cholesterol diet (HFHCD) for 16 weeks to induce early MASH without fibrosis and treated with the anti-MASH drug semaglutide for 8 weeks after modeling. Longitudinal MRI assessments—including proton density fat fraction (PDFF), 1 H magnetic resonance spectroscopy (MRS), T 2 mapping, and diffusion-weighted imaging (DWI)—were performed every 4 weeks and correlated with histopathology. Results: Histology confirmed early MASH after 16 weeks, without fibrosis. All MRI parameters strongly correlated with histopathological scores. HFHCD feeding led to significant changes: PDFF, MRS-derived liver fat content (LFC), and T 2 values increased by 6.8-, 5.2-, and 2.5-fold, respectively, while apparent diffusion coefficient (ADC) decreased by 30% ( p < 0.001). T 2 and ADC also correlated with MRS-quantified saturated fatty acids. Semaglutide treatment effectively reversed these changes: PDFF decreased by 73%, LFC by 62%, T 2 by 46% ( p < 0.001), and ADC increased 1.4-fold ( p = 0.017) compared to the vehicle group. Conclusion: This work demonstrates multiparametric MRI as a powerful noninvasive platform for monitoring early MASH dynamics and treatment response. By enabling longitudinal assessment in a prefibrotic model, this approach accelerates translational research in MASH diagnosis and drug development. Relevance statement: The established multiparametric MRI evaluation system provides a valuable noninvasive monitoring platform for preclinical early-stage MASH research, demonstrating significant potential to accelerate the translational progress in MASH diagnosis and drug development. Key Points: A novel prefibrotic MASH model was established to assess early-stage MASH progression. Multiparametric MRI at 9.4 T enables noninvasive, longitudinal monitoring of early MASH. Semaglutide-induced improvement in steatosis and inflammation can be monitored by multiparametric MRI. Graphical
- Open Access
- 1 May 2026
- Published by KEAI Publishing in Fundamental Research
- Vol. 6 (3) , 1249-1250
Biomedical imaging
- 1 May 2026
- Published by KEAI Publishing in Fundamental Research
- Vol. 6 (3) , 1249-1250
Open AccessBiomedical imaging
- Open Access
- 14 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Rational design of a Kappa opioid receptor peptide agonist with attenuated β-arrestin signaling
Difelikefalin is an FDA-approved κ-opioid receptor (KOR) peptide agonist used to treat chronic pruritus. However, as a balanced agonist that activates both G protein and β-arrestin pathways, difelikefalin remains associated with undesirable side effects linked to β-arrestin signaling. Here, we report the cryo-EM structure of the difelikefalin-KOR-Gi complex, identifying Y320 7.43 as a key residue that is critical for signaling bias. Guided by this structural insight, we engineer beta01, a β-amino acid-substituted analog with potent G protein activation but minimal β-arrestin recruitment. In mouse models, beta01 retains robust antinociceptive and antipruritic efficacy while significantly reducing sedation and anxiety-like behaviors. Structural, molecular dynamics simulations and 2D 13 C-Met NMR analyses further reveal beta01 stabilizes a unique KOR conformation with an expanded intracellular cavity that disfavors β-arrestin binding. This work establishes a rational structure-based framework for designing safer and more effective GPCR-targeted therapeutics.
- 14 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessRational design of a Kappa opioid receptor peptide agonist with attenuated β-arrestin signaling
Difelikefalin is an FDA-approved κ-opioid receptor (KOR) peptide agonist used to treat chronic pruritus. However, as a balanced agonist that activates both G protein and β-arrestin pathways, difelikefalin remains associated with undesirable side effects linked to β-arrestin signaling. Here, we report the cryo-EM structure of the difelikefalin-KOR-Gi complex, identifying Y320 7.43 as a key residue that is critical for signaling bias. Guided by this structural insight, we engineer beta01, a β-amino acid-substituted analog with potent G protein activation but minimal β-arrestin recruitment. In mouse models, beta01 retains robust antinociceptive and antipruritic efficacy while significantly reducing sedation and anxiety-like behaviors. Structural, molecular dynamics simulations and 2D 13 C-Met NMR analyses further reveal beta01 stabilizes a unique KOR conformation with an expanded intracellular cavity that disfavors β-arrestin binding. This work establishes a rational structure-based framework for designing safer and more effective GPCR-targeted therapeutics.
- 11 April 2026
- Published by Wiley in Angewandte Chemie
- Vol. 138 (20)
Spin‐Polarized Chiral ZnIn 2 S 4 for Targeted Solar‐Driven CO 2 Reduction to Acetic Acid
Acetic acid represents a pivotal target for CO 2 reduction due to its dual function as a carbon‐utilization product and industrial feedstock. However, photocatalytic CO 2 reduction (PCCR) to acetic acid typically suffers from low acetic acid yields and selectivity, constrained by competing reactions from ethanol and inefficient C–C coupling. Herein, we report a chiral mesostructured ZnIn 2 S 4 (CMZI) photocatalyst that achieves a remarkable acetic acid yield of 962 µmol g −1 h −1 with a high selectivity of 97.3%. This performance stems from synergistic chirality‐induced spin polarization and sulfur site catalysis. Spin polarization stabilizes the triplet OCCO intermediate to enhance C–C coupling, while sulfur sites on ZnIn 2 S 4 {102} facets thermodynamically and kinetically favor acetic acid formation. This work offers critical insights into catalytic strategies of the efficient synthesis of high‐value multicarbon products and expanding the variety of synthetic products from CO 2 reduction.
- 11 April 2026
- Published by Wiley in Angewandte Chemie
- Vol. 138 (20)
Spin‐Polarized Chiral ZnIn 2 S 4 for Targeted Solar‐Driven CO 2 Reduction to Acetic Acid
Acetic acid represents a pivotal target for CO 2 reduction due to its dual function as a carbon‐utilization product and industrial feedstock. However, photocatalytic CO 2 reduction (PCCR) to acetic acid typically suffers from low acetic acid yields and selectivity, constrained by competing reactions from ethanol and inefficient C–C coupling. Herein, we report a chiral mesostructured ZnIn 2 S 4 (CMZI) photocatalyst that achieves a remarkable acetic acid yield of 962 µmol g −1 h −1 with a high selectivity of 97.3%. This performance stems from synergistic chirality‐induced spin polarization and sulfur site catalysis. Spin polarization stabilizes the triplet OCCO intermediate to enhance C–C coupling, while sulfur sites on ZnIn 2 S 4 {102} facets thermodynamically and kinetically favor acetic acid formation. This work offers critical insights into catalytic strategies of the efficient synthesis of high‐value multicarbon products and expanding the variety of synthetic products from CO 2 reduction.